Sinovac Biotech (SVA) 5.24 $SVA
Rabies Therapeutic Market Pipeline Overview, Assessment, Key Players & Drugs Profiles H2 2014
PRWeb - Wed Nov 12, 8:30PM CST
The report "Rabies - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Rabies, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rabies and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/rabies-pipel...eport.html .
NVAX: 5.19 (-0.05), KMDA: 3.41 (-0.09), VBIV: 2.47 (-0.01), NNVC: 3.47 (-0.02), SVA: 5.24 (-0.02)
Sinovac to Host Conference Call to Report Third Quarter 2014 Unaudited Financial Results
PR Newswire - Wed Nov 05, 3:00AM CST
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the third quarter, ended September 30, 2014, after market close on Friday, November 14, 2014 ET. The Company will host a conference call prior to the market opening on Monday, November 17, 2014, at 8:00 a.m. ET (Monday, November 17, 2014 at 9:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent corporate developments.
SVA: 5.24 (-0.02)
Simavita Limited: Pilots Drive Further SIM(TM) Growth in Australia, US and Europe
Marketwired - Mon Nov 03, 4:02PM CST
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) -
SV.VN: 0.620 (+0.170), SVA: 5.24 (-0.02)
Global Pediatric Vaccine Market 2014-2018: Key Vendors are GlaxoSmithKline, Merck, Pfizer and Sanofi
M2 - Fri Oct 31, 3:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zmnrcn/global_pediatric) has announced the addition of the "Global Pediatric Vaccine Market 2014-2018" report to their offering. Pediatric vaccines are used for the immunization of children and adolescents against various infectious diseases, such as diphtheria, influenza, hepatitis, pneumococcal diseases, and meningococcal diseases. According to the US FDA, pediatric age ranges are classified as newborn, infant, child, and adolescent, ranging from birth to 21 years. However, the EMA classifies pediatric age range from birth to 18 years. The analysts forecast the Global Pediatric Vaccine market to grow at a CAGR of 10.25 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Pediatric Vaccine market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various approved vaccines. The report, the Global Pediatric Vaccine Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Pediatric Vaccine market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Route of Administration 08. Market Segmentation by Product Type 09. Geographical Segmentation 10. Key Leading Countries 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Trends and their Impact 18. Vendor Landscape 19. Key Vendor Analysis 20. Other Reports in this Series Companies Mentioned: - AstraZeneca - Bavarian Nordic - Baxter - Bharat Biotech - Bharat Immunologicals and Biologicals - Bio Med - Crucell - Dynavax Technologies - GlaxoSmithKline - Indian Immunologicals - Janssen - Kaketsuken - LG Life Sciences - Lupin - Merck - Mitsubishi Tanabe Pharma - Novartis - Nuron - Panacea Biotec - Pfizer - S K Chemicals - Sanofi - Serum Institute of India - Shenzhen Kangtai Biological Products - Sinovac Biotech - Takeda Pharmaceutical - Valeant Pharmaceuticals - Zydus Cadila - bioCSL For more information visit http://www.researchandmarkets.com/research/zm..._pediatric
DVAX: 15.60 (-0.44), MRK: 59.54 (+0.23), GSK: 45.66 (+0.04), SVA: 5.24 (-0.02), NVS: 94.38 (+1.72)
Simavita Releases Materials for 2014 Annual General and Special Meeting
Marketwired - Thu Oct 30, 5:32PM CDT
Simavita Limited (TSX VENTURE: SV)(ASX: SVA) ("Simavita" or the "Company"
is pleased to release the materials for its 2014 Annual General and Special Meeting (the "Meeting" .
SV.VN: 0.620 (+0.170), SVA: 5.24 (-0.02)
Sinovac to Participate in Jefferies 4th Annual Asia Summit
PR Newswire - Tue Oct 21, 5:06AM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that the Company's management will host investor meetings at the Jefferies 4th Annual Asia Summit, to be held at the Island Shangri-La Hotel in Hong Kong on October 29-30, 2014. Please contact your Jefferies institutional sales representative to schedule a meeting with the Company.
SVA: 5.24 (-0.02)
PMT, BPOPM, EXAS, SVA, SGG Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Fri Oct 10, 4:20AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Perpetual Energy Inc (NYSE
MT), Popular Capital Trust II (NASDAQ:BPOPM), Exact Sciences Corp (NASDAQ:EXAS), Sernova Corp (NASDAQ:SVA), SnipGold Corp (NYSE:SGG) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
SGG: 41.27 (-0.73), PMT: 21.69 (+0.13), EXAS: 23.11 (+0.61), SVA: 5.24 (-0.02), BPOPM: 20.91 (-0.04)
Sinovac Biotech Shares Down 10.5% Since SmarTrend's Sell Call (SVA)
Comtex SmarTrend(R) - Wed Oct 08, 5:08PM CDT
SmarTrend identified a Downtrend for Sinovac Biotech (AMEX:SVA) on April 15th, 2014 at $5.88. In approximately 6 months, Sinovac Biotech has returned 10.54% as of today's recent price of $5.26.
SVA: 5.24 (-0.02)
3 Biotech Stocks Under $10 in Breakout Territory
at The Street - Wed Oct 08, 7:30AM CDT
Keep these under-$10 biotech stocks on your breakout trading radar.
OXGN: 1.76 (+0.01), NVAX: 5.19 (-0.05), SVA: 5.24 (-0.02)
Shares of SVA Down 14.3% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Sep 17, 4:57PM CDT
SmarTrend identified a Downtrend for Sinovac Biotech (AMEX:SVA) on April 15th, 2014 at $5.88. In approximately 5 months, Sinovac Biotech has returned 14.29% as of today's recent price of $5.04.
SVA: 5.24 (-0.02)
Lorien Health Systems to Roll out SIM(TM) Across its US Facilities
Marketwire - Tue Sep 16, 1:33PM CDT
Simavita Limited (ASX: SVA) (TSX VENTURE: SV) ("Simavita" or the "Company" is pleased to announce that the Company's exclusive US distribution partner, Medline Industries, Inc. ("Medline" , has advised that it has executed an agreement under which it will roll out Simavita's SIM(TM) incontinence assessment and management solution across all of the Skilled Nursing facilities operated by US aged care provider, Lorien Health Systems ("Lorien".)
SV.VN: 0.620 (+0.170), SVA: 5.24 (-0.02)
Lorien Health Systems to Roll Out Simavita's SIM(TM) across Its US Facilities
Business Wire - Tue Sep 16, 8:00AM CDT
--Leading US aged care services provider, Lorien Health Systems to roll out Simavita's SIM(TM) Smart Incontinence Management system across all of its skilled nursing facilities
SV.VN: 0.620 (+0.170), SVA: 5.24 (-0.02)
Simavita Limited: Resignation of Chairman
Marketwire - Fri Sep 12, 11:27AM CDT
Simavita Limited (ASX: SVA) (TSX VENTURE: SV) ("Simavita" or the "Company" announces the decision of the Company's Chairman, Mr. Peter Cook, to resign as a Director of Simavita, with immediate effect.
SV.VN: 0.620 (+0.170), SVA: 5.24 (-0.02)
Tetanus Therapeutics Pipeline Review, H2 2014 - 15 Companies with 29 Drug Profiles
M2 - Tue Sep 09, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qnddk4/tetanus) has announced the addition of the "Tetanus - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tetanus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tetanus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - Takeda Pharmaceutical Company Limited - Biological E. Limited - Novartis AG - Zydus Cadila Healthcare Limited - Green Cross Corporation - LG Life Sciences, Ltd. - Bharat Biotech International Limited - Sinovac Biotech Ltd. - Serum Institute of India Limited - Indian Immunologicals Limited - Beijing Minhai Biotechnology Co., Ltd - Sanofi Pasteur SA Drug Profiles - diphtheria tetanus toxoids acellular pertussis vaccine adsorbed combined with inactivated poliomyelitis vaccine - tetanus toxoid reduced diphtheria toxoid acellular pertussis vaccine adsorbed - DtwP-HB-Hib (liq) Vaccine - diphtheria tetanus pertussis (acellular) hepatitis B poliomyelitis (inactivated) haemophilus influenza polysaccharide conjugate [serogroup B] vaccine - GC-1107 - DTwP-HBV-Hib - VN-0103 - Hexavalent DTwP-Hepb-Hib-IPV Vaccine - Pentavalent DTwP-Hib-IPV Vaccine - GSK-217744 - TAK-361S - diphtheria tetanus pertussis vaccine - diphtheria tetanus pertussis (acellular) vaccine - diphtheria pertussis tetanus vaccine - diphtheria pertussis tetanus vaccine - Tetanus Vaccine - Toxoid Vaccine for Diptheria and Tetanus - Vaccine for Diptheria, Tetanus and Pertussis - Diptheria Tetanus Pertussis And Haemophilus Type B Conjugate Vaccine - GC-3111A - DTwP-IPV - DTaP Vaccine - Diphtheria Tetanus Pertussis (Acellular) Vaccine - DPT-H-HiB Vaccine - Tetanus Vaccine - tetanus vaccine - DTwP-Hep B-IPV-Hib - DTwP-IPV Hib - DTwP Hib For more information visit http://www.researchandmarkets.com/research/qnddk4/tetanus
GSK: 45.66 (+0.04), SVA: 5.24 (-0.02), NVS: 94.38 (+1.72)
Rabies Therapeutic Market Pipeline Overview, Assessment, Key Players & Drugs Profiles H2 2014
PRWeb - Wed Nov 12, 8:30PM CST
The report "Rabies - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Rabies, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rabies and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/rabies-pipel...eport.html .
NVAX: 5.19 (-0.05), KMDA: 3.41 (-0.09), VBIV: 2.47 (-0.01), NNVC: 3.47 (-0.02), SVA: 5.24 (-0.02)
Sinovac to Host Conference Call to Report Third Quarter 2014 Unaudited Financial Results
PR Newswire - Wed Nov 05, 3:00AM CST
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the third quarter, ended September 30, 2014, after market close on Friday, November 14, 2014 ET. The Company will host a conference call prior to the market opening on Monday, November 17, 2014, at 8:00 a.m. ET (Monday, November 17, 2014 at 9:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent corporate developments.
SVA: 5.24 (-0.02)
Simavita Limited: Pilots Drive Further SIM(TM) Growth in Australia, US and Europe
Marketwired - Mon Nov 03, 4:02PM CST
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) -
SV.VN: 0.620 (+0.170), SVA: 5.24 (-0.02)
Global Pediatric Vaccine Market 2014-2018: Key Vendors are GlaxoSmithKline, Merck, Pfizer and Sanofi
M2 - Fri Oct 31, 3:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zmnrcn/global_pediatric) has announced the addition of the "Global Pediatric Vaccine Market 2014-2018" report to their offering. Pediatric vaccines are used for the immunization of children and adolescents against various infectious diseases, such as diphtheria, influenza, hepatitis, pneumococcal diseases, and meningococcal diseases. According to the US FDA, pediatric age ranges are classified as newborn, infant, child, and adolescent, ranging from birth to 21 years. However, the EMA classifies pediatric age range from birth to 18 years. The analysts forecast the Global Pediatric Vaccine market to grow at a CAGR of 10.25 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Pediatric Vaccine market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various approved vaccines. The report, the Global Pediatric Vaccine Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Pediatric Vaccine market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Route of Administration 08. Market Segmentation by Product Type 09. Geographical Segmentation 10. Key Leading Countries 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Trends and their Impact 18. Vendor Landscape 19. Key Vendor Analysis 20. Other Reports in this Series Companies Mentioned: - AstraZeneca - Bavarian Nordic - Baxter - Bharat Biotech - Bharat Immunologicals and Biologicals - Bio Med - Crucell - Dynavax Technologies - GlaxoSmithKline - Indian Immunologicals - Janssen - Kaketsuken - LG Life Sciences - Lupin - Merck - Mitsubishi Tanabe Pharma - Novartis - Nuron - Panacea Biotec - Pfizer - S K Chemicals - Sanofi - Serum Institute of India - Shenzhen Kangtai Biological Products - Sinovac Biotech - Takeda Pharmaceutical - Valeant Pharmaceuticals - Zydus Cadila - bioCSL For more information visit http://www.researchandmarkets.com/research/zm..._pediatric
DVAX: 15.60 (-0.44), MRK: 59.54 (+0.23), GSK: 45.66 (+0.04), SVA: 5.24 (-0.02), NVS: 94.38 (+1.72)
Simavita Releases Materials for 2014 Annual General and Special Meeting
Marketwired - Thu Oct 30, 5:32PM CDT
Simavita Limited (TSX VENTURE: SV)(ASX: SVA) ("Simavita" or the "Company"
is pleased to release the materials for its 2014 Annual General and Special Meeting (the "Meeting" . SV.VN: 0.620 (+0.170), SVA: 5.24 (-0.02)
Sinovac to Participate in Jefferies 4th Annual Asia Summit
PR Newswire - Tue Oct 21, 5:06AM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that the Company's management will host investor meetings at the Jefferies 4th Annual Asia Summit, to be held at the Island Shangri-La Hotel in Hong Kong on October 29-30, 2014. Please contact your Jefferies institutional sales representative to schedule a meeting with the Company.
SVA: 5.24 (-0.02)
PMT, BPOPM, EXAS, SVA, SGG Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Fri Oct 10, 4:20AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Perpetual Energy Inc (NYSE
MT), Popular Capital Trust II (NASDAQ:BPOPM), Exact Sciences Corp (NASDAQ:EXAS), Sernova Corp (NASDAQ:SVA), SnipGold Corp (NYSE:SGG) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: SGG: 41.27 (-0.73), PMT: 21.69 (+0.13), EXAS: 23.11 (+0.61), SVA: 5.24 (-0.02), BPOPM: 20.91 (-0.04)
Sinovac Biotech Shares Down 10.5% Since SmarTrend's Sell Call (SVA)
Comtex SmarTrend(R) - Wed Oct 08, 5:08PM CDT
SmarTrend identified a Downtrend for Sinovac Biotech (AMEX:SVA) on April 15th, 2014 at $5.88. In approximately 6 months, Sinovac Biotech has returned 10.54% as of today's recent price of $5.26.
SVA: 5.24 (-0.02)
3 Biotech Stocks Under $10 in Breakout Territory
at The Street - Wed Oct 08, 7:30AM CDT
Keep these under-$10 biotech stocks on your breakout trading radar.
OXGN: 1.76 (+0.01), NVAX: 5.19 (-0.05), SVA: 5.24 (-0.02)
Shares of SVA Down 14.3% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Sep 17, 4:57PM CDT
SmarTrend identified a Downtrend for Sinovac Biotech (AMEX:SVA) on April 15th, 2014 at $5.88. In approximately 5 months, Sinovac Biotech has returned 14.29% as of today's recent price of $5.04.
SVA: 5.24 (-0.02)
Lorien Health Systems to Roll out SIM(TM) Across its US Facilities
Marketwire - Tue Sep 16, 1:33PM CDT
Simavita Limited (ASX: SVA) (TSX VENTURE: SV) ("Simavita" or the "Company"
is pleased to announce that the Company's exclusive US distribution partner, Medline Industries, Inc. ("Medline" , has advised that it has executed an agreement under which it will roll out Simavita's SIM(TM) incontinence assessment and management solution across all of the Skilled Nursing facilities operated by US aged care provider, Lorien Health Systems ("Lorien".) SV.VN: 0.620 (+0.170), SVA: 5.24 (-0.02)
Lorien Health Systems to Roll Out Simavita's SIM(TM) across Its US Facilities
Business Wire - Tue Sep 16, 8:00AM CDT
--Leading US aged care services provider, Lorien Health Systems to roll out Simavita's SIM(TM) Smart Incontinence Management system across all of its skilled nursing facilities
SV.VN: 0.620 (+0.170), SVA: 5.24 (-0.02)
Simavita Limited: Resignation of Chairman
Marketwire - Fri Sep 12, 11:27AM CDT
Simavita Limited (ASX: SVA) (TSX VENTURE: SV) ("Simavita" or the "Company"
announces the decision of the Company's Chairman, Mr. Peter Cook, to resign as a Director of Simavita, with immediate effect. SV.VN: 0.620 (+0.170), SVA: 5.24 (-0.02)
Tetanus Therapeutics Pipeline Review, H2 2014 - 15 Companies with 29 Drug Profiles
M2 - Tue Sep 09, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qnddk4/tetanus) has announced the addition of the "Tetanus - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tetanus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tetanus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - Takeda Pharmaceutical Company Limited - Biological E. Limited - Novartis AG - Zydus Cadila Healthcare Limited - Green Cross Corporation - LG Life Sciences, Ltd. - Bharat Biotech International Limited - Sinovac Biotech Ltd. - Serum Institute of India Limited - Indian Immunologicals Limited - Beijing Minhai Biotechnology Co., Ltd - Sanofi Pasteur SA Drug Profiles - diphtheria tetanus toxoids acellular pertussis vaccine adsorbed combined with inactivated poliomyelitis vaccine - tetanus toxoid reduced diphtheria toxoid acellular pertussis vaccine adsorbed - DtwP-HB-Hib (liq) Vaccine - diphtheria tetanus pertussis (acellular) hepatitis B poliomyelitis (inactivated) haemophilus influenza polysaccharide conjugate [serogroup B] vaccine - GC-1107 - DTwP-HBV-Hib - VN-0103 - Hexavalent DTwP-Hepb-Hib-IPV Vaccine - Pentavalent DTwP-Hib-IPV Vaccine - GSK-217744 - TAK-361S - diphtheria tetanus pertussis vaccine - diphtheria tetanus pertussis (acellular) vaccine - diphtheria pertussis tetanus vaccine - diphtheria pertussis tetanus vaccine - Tetanus Vaccine - Toxoid Vaccine for Diptheria and Tetanus - Vaccine for Diptheria, Tetanus and Pertussis - Diptheria Tetanus Pertussis And Haemophilus Type B Conjugate Vaccine - GC-3111A - DTwP-IPV - DTaP Vaccine - Diphtheria Tetanus Pertussis (Acellular) Vaccine - DPT-H-HiB Vaccine - Tetanus Vaccine - tetanus vaccine - DTwP-Hep B-IPV-Hib - DTwP-IPV Hib - DTwP Hib For more information visit http://www.researchandmarkets.com/research/qnddk4/tetanus
GSK: 45.66 (+0.04), SVA: 5.24 (-0.02), NVS: 94.38 (+1.72)
